Hims & Hers Health (NYSE:HIMS) Rating Increased to Neutral at Citigroup

Hims & Hers Health (NYSE:HIMS) was upgraded by Citigroup from a “sell” rating to a “neutral” rating in a report issued on Tuesday. The brokerage presently has a $24.00 target price on the stock. Citigroup’s price objective points to a potential upside of 8.50% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Barclays reduced their price objective on shares of Hims & Hers Health from $48.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 24th. TD Cowen dropped their price target on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a research report on Tuesday, February 24th. Bank of America upgraded shares of Hims & Hers Health from an “underperform” rating to a “neutral” rating and upped their price target for the company from $12.50 to $23.00 in a research report on Tuesday. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, BTIG Research cut shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $30.46.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $22.12 on Tuesday. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The company’s fifty day simple moving average is $24.51 and its 200-day simple moving average is $37.89. The company has a market cap of $5.04 billion, a PE ratio of 43.37, a P/E/G ratio of 3.01 and a beta of 2.56. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS. As a group, equities research analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health declared that its board has authorized a share buyback program on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Deborah M. Autor sold 7,054 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the sale, the insider directly owned 6,175 shares in the company, valued at approximately $226,684.25. The trade was a 53.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the transaction, the insider owned 2,126 shares in the company, valued at $78,045.46. This represents a 79.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 80,463 shares of company stock valued at $2,846,696 in the last quarter. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Virtus Advisers LLC purchased a new stake in Hims & Hers Health during the second quarter valued at approximately $26,000. Quent Capital LLC purchased a new stake in Hims & Hers Health in the 3rd quarter worth approximately $28,000. Flagship Harbor Advisors LLC purchased a new position in Hims & Hers Health during the fourth quarter valued at approximately $28,000. Binnacle Investments Inc purchased a new stake in Hims & Hers Health in the 3rd quarter worth approximately $28,000. Finally, Bogart Wealth LLC lifted its holdings in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk deal ends legal feud and opens GLP‑1 distribution — reports say Novo will sell Wegovy and Ozempic via Hims’ platform, removing a major litigation overhang and enabling direct access to high‑margin, in‑demand therapies. This is the primary driver of the rally. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit (Reuters)
• Positive Sentiment: Analysts raise ratings and price targets — Needham upgraded HIMS to Buy with a $30 PT, Deutsche Bank raised its PT to $28 (Hold), and Bank of America moved from Underperform to Neutral with a $23 PT; these upward revisions support the stock’s rally. Analyst updates (Benzinga)
• Neutral Sentiment: Potential commercial and margin upside — coverage notes the deal could reshape HIMS’ GLP‑1 strategy and improve margins by offering branded products rather than competing with compounded versions; timing and revenue contribution are still uncertain. Hims & Hers Health Soars on Novo Nordisk Weight‑Loss Drug Deal (The Motley Fool)
• Neutral Sentiment: Short‑squeeze dynamics — several pieces flag very high short interest and the potential for a squeeze that can push shares sharply higher in the near term but also amplify volatility when it unwinds. That increases trading risk even as it supports near‑term gains. Short‑squeeze analysis (Seeking Alpha)
• Negative Sentiment: Investor probe and lingering legal/regulatory risk — a shareholder law firm has opened an investigation into Hims’ officers and directors stemming from the earlier Novo dispute and related issues; this keeps potential governance and legal liabilities on the table. Investigation initiated (BusinessWire)
• Negative Sentiment: Questions about sustainability — coverage warns the big one‑day gains may not be durable; if the Novo distribution ramps slower than hoped or if sentiment reverses after a short squeeze, shares could retrace quickly. Gains may be unsustainable (Invezz)

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.